Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease

• ClinicalTrials.gov Identifier: NCT02151643
• Recruitment Status: Completed
• First Posted: May 30, 2014
• Results First Posted: January 16, 2018
• Last Update Posted: January 16, 2018
• Sponsor: Phosphate Therapeutics
• Collaborator: Clinipace Worldwide
• Information provided by (Responsible Party): Phosphate Therapeutics

Study Description

Brief Summary:

The main purpose of this study is to see whether PT20 can help people with a high level of phosphate in their blood (called Hyperphosphatemia) that are being treated with dialysis for kidney disease.

Condition or disease	Intervention/treatment	Phase
Hyperphosphataemia	Drug: PT20; Drug: Placebo	Phase 2

Detailed Description:

PT20 represents a mechanism to address many of the limitations associated with current phosphate binding agents. The available clinical and non clinical evidence suggests that PT20 binds phosphate and prevents its uptake more efficiently than other phosphate binding drugs and may therefore either reduce the pill burden associated with controlling phosphate levels, or result in lower phosphate levels with the same pill burden.

The this study is the first to investigate the efficacy and safety of PT20 in subjects with dialysis-dependent chronic kidney disease (CKD).

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 153 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease
• Actual Study Start Date: May 7, 2014
• Actual Primary Completion Date: March 18, 2015
• Actual Study Completion Date: March 18, 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: Group 1 - PT20 400 mg tid; PT20 400 mg tid (1.2 g/day) administered orally. Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study	Drug: PT20; Modified ferric oxide adipate tablets; Other Names: Iron (III) oxide adipate; ferric oxide adipate; iron (III) oxide hydroxide adipate; M10L78
Experimental: Group 2 - PT20 800 mg tid; PT20 800 mg tid (2.4 g/day) administered orally. Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study	Drug: PT20; Modified ferric oxide adipate tablets; Other Names: Iron (III) oxide adipate; ferric oxide adipate; iron (III) oxide hydroxide adipate; M10L78
Experimental: Group 3 - PT20 1600 mg tid; PT20 1600 mg tid (4.8 g/day) administered orally. Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study	Drug: PT20; Modified ferric oxide adipate tablets; Other Names: Iron (III) oxide adipate; ferric oxide adipate; iron (III) oxide hydroxide adipate; M10L78
Experimental: Group 4 - PT20 3200 mg tid; PT20 3200 mg tid (9.6 g/day) administered orally. Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study	Drug: PT20; Modified ferric oxide adipate tablets; Other Names: Iron (III) oxide adipate; ferric oxide adipate; iron (III) oxide hydroxide adipate; M10L78
Placebo Comparator: Group 5 - Placebo tid; Matched Placebo (for PT20) tid administered orally. Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study	Drug: Placebo; Placebo tablets matched to each PT20 dose arm; Other Name: Matched Placebo for PT20

Outcome Measures

Primary Outcome Measures :

1. Change in Serum Phosphate Concentration From Baseline (Visit 7, Day 1) to Visit 11 (Day 29) [ Time Frame: Day 1 to Day 29 ]
   The primary efficacy endpoint was the change in serum phosphate concentration from Baseline (Visit 7, Day 1) to Visit 11 (Day 29). All study specific blood samples were collected, processed and analysed using a central laboratory.

Secondary Outcome Measures :

1. Change in Haemoglobin Concentration From Baseline (Visit 7, Day 1) to Visit 11 (Day 29) [ Time Frame: Day 1 to Day 29 ]
   Descriptive statistics were to be used to summarise values and change from Baseline (Visit 7, Day 1) to Day 29 (Visit 11) in haemoglobin concentration. An analysis of covariance (ANCOVA) was to be used to analyse the changes from Baseline (Visit 7, Day 1) to Visit 11 (Day 29), which were to include the fixed, categorical effects of treatment as well as the continuous, fixed covariates of Baseline concentrations for haemoglobin. Only those subjects with available concentrations for both Baseline (Visit 7, Day 1) and Visit 11 (Day 29) were to be included in this analysis.
2. Change in Serum Ferritin Concentration From Baseline (Visit 7, Day 1) to Visit 11 (Day 29) [ Time Frame: Day 1 to Day 29 ]
   Descriptive statistics were to be used to summarise values and change from Baseline (Visit 7, Day 1) to Day 29 (Visit 11) in serum ferritin concentration. An analysis of covariance (ANCOVA) was to be used to analyse the changes from Baseline (Visit 7, Day 1) to Visit 11 (Day 29), which were to include the fixed, categorical effects of treatment and week (Visit), as well as the continuous, fixed covariates of Baseline concentrations for serum ferritin. Only those subjects with available concentrations for both Baseline (Visit 7, Day 1) and Visit 11 (Day 29) were to be included in this analysis.
3. Change in Transferrin Saturation From Baseline (Visit 7, Day 1) to Visit 11 (Day 29) [ Time Frame: Day 1 to Day 29 ]
   Descriptive statistics were to be used to summarise values and change from Baseline (Visit 7, Day 1) to Day 29 (Visit 11) in transferrin saturation. An analysis of covariance (ANCOVA) was to be used to analyse the changes from Baseline (Visit 7, Day 1) to Day 29 (Visit 11), which were to include the fixed, categorical effects of treatment and week, as well as the continuous, fixed covariates of Baseline concentrations for transferrin saturation. Only those subjects with available concentrations for both Baseline (Visit 7, Day 1) and Visit 11 (Day 29) were to be included in this analysis.
4. Change in Calcium x Phosphate Product From Baseline (Visit 7, Day 1) to Visit 11 (Day 29) [ Time Frame: Day 1 to Day 29 ]
   Descriptive statistics were to be used to summarise values and change from Baseline (Visit 7, Day 1) to Day 29 (Visit 11) in Calcium x Phosphate Product . An analysis of covariance (ANCOVA) was to be used to analyse the changes from Baseline (Visit 7, Day 1) to Day 29 (Visit 11), which were to include the fixed, categorical effects of treatment, as well as the continuous, fixed covariates of Baseline concentrations for Calcium x Phosphate Product. Only those subjects with available concentrations for both Baseline (Visit 7, Day 1) and Visit 11 (Day 29) were to be included in this analysis. In CKD subjects (Stages 3-5), the clinical recommendation (KDOQI) is that serum calcium x phosphate product should be maintained at < 55 mg^2/dL^2 (4.4 mmol^2 /L^2).
5. Change in Gastrointestinal Symptom Rating System (GSRS) Overall Score From Baseline (Visit 7, Day 1) to Visit 11 (Day 29) [ Time Frame: Day 1 to Day 29 ]
   The GSRS assesses the impact of treatment-related GI complications. It includes 15 items divided into 5 subscales (diarrhoea, indigestion, abdominal pain, constipation, and reflux), and uses a seven-grade Likert scale to assess symptoms (1 = no discomfort at all, 7 = very severe discomfort). The total score was calculated as the average score of all 15 items. If data were missing from one or more subscales, the mean of the completed items within the subscale was to be used for the subscale score, provided that more than half of the subscale items were complete. If more than half of the items within a subscale were missing, the subscale score and overall score were also to be defined as missing. The change in overall GSRS score from Baseline (Visit 7, Day 1) to Visit 11 (Day 29) was summarised by treatment and a two-sample t-test was to be used to identify differences between the placebo and PT20 dose groups. The higher the score, the more severe the gastrointestinal symptoms.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 90 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Men or women aged 18 90 years
• Subject must have a stable dialysis prescription for at least 28 days prior to start of Screening.
• Subject must have the most recent serum phosphate measurement, taken during the 28 days prior to the start of Screening, of ≥ 4.0 mg/dL and ≤ 8 mg/dL.

Exclusion Criteria:

• Subject's most recent historical pre-dialysis serum bicarbonate value within 14 days prior to the start of Screening (Visit 1) is < 18 mg/dL.
• Subject has, in the opinion of the investigator, severe chronic lung disease and/or carbon dioxide retention.

Contacts and Locations

Sponsors and Collaborators

Phosphate Therapeutics

Clinipace Worldwide

Investigators

• Principal Investigator: Geoff Block, MD; Denver Nephrologist

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Sampson M, Faria N, Powell JJ; PEACH study investigators. Efficacy and safety of PT20, an iron-based phosphate binder, for the treatment of hyperphosphataemia: a randomized, double-blind, placebo-controlled, dose-ranging, Phase IIb study in patients with haemodialysis-dependent chronic kidney disease. Nephrol Dial Transplant. 2021 Jul 23;36(8):1399-1407. doi: 10.1093/ndt/gfaa116.

• Responsible Party: Phosphate Therapeutics
• ClinicalTrials.gov Identifier: NCT02151643
• Other Study ID Numbers: PT20-201
• First Posted: May 30, 2014
• Results First Posted: January 16, 2018
• Last Update Posted: January 16, 2018
• Last Verified: December 2017

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Phosphate Therapeutics:

Dialysis Dependent Chronic Kidney Disease

Additional relevant MeSH terms:

Kidney Diseases; Renal Insufficiency, Chronic; Hyperphosphatemia; Urologic Diseases; Renal Insufficiency; Phosphorus Metabolism Disorders; Metabolic Diseases; Iron; Trace Elements; Micronutrients; Physiological Effects of Drugs